Xiangjie Lu - Search Results

Year	Number of Results
2002	1
2007	3
2008	3
2009	3
2010	5
2011	3
2012	5
2013	9
2014	12
2015	17
2016	26
2017	30
2018	32
2019	29
2020	20
2021	22
2022	29
2023	33
2024	13

1

PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets.

Chen H, Tan H, Wan J, Zeng Y, Wang J, Wang H, Lu X. Chen H, et al. Among authors: lu x. Pharmacol Ther. 2023 May;245:108391. doi: 10.1016/j.pharmthera.2023.108391. Epub 2023 Mar 22. Pharmacol Ther. 2023. PMID: 36963510 Review.

2

The markers and risk stratification model of intracranial aneurysm instability in a large Chinese cohort.

Liu Q, Li K, He H, Miao Z, Cui H, Wu J, Ding S, Wen Z, Chen J, Lu X, Li J, Zheng L, Wang S. Liu Q, et al. Among authors: lu x. Sci Bull (Beijing). 2023 Jun 15;68(11):1162-1175. doi: 10.1016/j.scib.2023.05.001. Epub 2023 May 10. Sci Bull (Beijing). 2023. PMID: 37210332 Free article.

3

Cancer immunotherapy: Current applications and challenges.

Sun JY, Lu XJ. Sun JY, et al. Cancer Lett. 2020 Jun 28;480:1-3. doi: 10.1016/j.canlet.2020.03.024. Epub 2020 Mar 27. Cancer Lett. 2020. PMID: 32229188 No abstract available.

4

Gut microbiome and cancer immunotherapy.

Sun JY, Yin TL, Zhou J, Xu J, Lu XJ. Sun JY, et al. J Cell Physiol. 2020 May;235(5):4082-4088. doi: 10.1002/jcp.29359. Epub 2019 Oct 29. J Cell Physiol. 2020. PMID: 31663125 Review.

5

Featuring the special issue guest editor.

Lu XJ. Lu XJ. Cancer Lett. 2020 May 28;478:70. doi: 10.1016/j.canlet.2020.03.003. Epub 2020 Mar 9. Cancer Lett. 2020. PMID: 32165271 No abstract available.

6

Gut Microbiota and Acute Central Nervous System Injury: A New Target for Therapeutic Intervention.

Yuan B, Lu XJ, Wu Q. Yuan B, et al. Front Immunol. 2021 Dec 24;12:800796. doi: 10.3389/fimmu.2021.800796. eCollection 2021. Front Immunol. 2021. PMID: 35003127 Free PMC article. Review.

7

Ruthenium-Promoted On-DNA C-H Activation Reaction.

Wang X, Lu X. Wang X, et al. Among authors: lu x. Methods Mol Biol. 2022;2541:63-66. doi: 10.1007/978-1-0716-2545-3_10. Methods Mol Biol. 2022. PMID: 36083545

8

Applications and advances of CRISPR-Cas9 in cancer immunotherapy.

Xia AL, He QF, Wang JC, Zhu J, Sha YQ, Sun B, Lu XJ. Xia AL, et al. J Med Genet. 2019 Jan;56(1):4-9. doi: 10.1136/jmedgenet-2018-105422. Epub 2018 Jul 3. J Med Genet. 2019. PMID: 29970486 Review.

9

T Cell Dysfunction in Cancer Immunity and Immunotherapy.

Xia A, Zhang Y, Xu J, Yin T, Lu XJ. Xia A, et al. Front Immunol. 2019 Jul 19;10:1719. doi: 10.3389/fimmu.2019.01719. eCollection 2019. Front Immunol. 2019. PMID: 31379886 Free PMC article. Review.

10

Therapeutic advances for patients with intermediate hepatocellular carcinoma.

Sun JY, Yin T, Zhang XY, Lu XJ. Sun JY, et al. J Cell Physiol. 2019 Aug;234(8):12116-12121. doi: 10.1002/jcp.28019. Epub 2019 Jan 15. J Cell Physiol. 2019. PMID: 30648254 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

250 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

250 results

Results by year